Must Know FDA Ruling Will Save Lives

Starting September 10, 2024, the U.S. Food and Drug Administration (FDA) introduced a key update under the Mammography Quality Standards Act (MQSA): all mammogram providers are now required to inform patients about their breast density following screenings.

According to the new standard, mammogram reports will identify whether a patient’s breast tissue is either dense or nondense. The patient will also be told that breast density can mask cancer on a mammogram, that breast density increases the risk of developing breast cancer, and that people with breast density may benefit from additional screening. While mammograms remain the primary tool for breast cancer screening, dense breast tissue requires additional imaging to reveal cancer that may be obscured by breast density. Ultrasound, MRI, MBI (Molecular Breast Imaging), or CEM (Contrast Enhanced Mammography) may be recommended in cases of dense tissue, providing a clearer picture that enhances mammography results.

This ruling ensures that after September 10, 2024, every woman who undergoes a mammogram will receive information about her breast density. For those with dense breasts, it is important to discuss the implications with a healthcare provider. Based on individual risk factors, family history, and preferences, further screenings may be beneficial.

We hope this new measure will lead to more proactive conversations between patients and doctors. By reading their reports, understanding their breast density, and having informed discussions with healthcare providers, women can now make informed and empowered choices about their additional breast cancer screening options.

Learn more about breast density at www.mydensitymatters.org or by texting "Check Your Chart" to 211-411.